FOLTA, Adam, Martin ČULEN, Ivana JEŽÍŠKOVÁ, Zdeňka HERUDKOVÁ, Nikola TOM, Tereza HLUBINKOVÁ, Veronika JANEČKOVÁ, Anna ĎURINÍKOVÁ, Jan VYDRA, Lukáš SEMERÁD, Dana DVOŘÁKOVÁ, Hana REMEŠOVÁ, Ela CEROVSKÁ, Petr CETKOVSKÝ, Pavel JINDRA, Tomáš SZOTKOWSKI, Pavel ŽÁK, Jiří MAYER and Zdeněk RÁČIL. Prognostic significance of mutation profile at diagnosis and mutation persistence during disease remission in adult acute myeloid leukaemia patients. British journal of haematology. England: Wiley-Blackwell, 2019, vol. 186, No 2, p. 300-310. ISSN 0007-1048. Available from: https://dx.doi.org/10.1111/bjh.15916.
Other formats:   BibTeX LaTeX RIS
Basic information
Original name Prognostic significance of mutation profile at diagnosis and mutation persistence during disease remission in adult acute myeloid leukaemia patients
Authors FOLTA, Adam, Martin ČULEN (703 Slovakia, belonging to the institution), Ivana JEŽÍŠKOVÁ, Zdeňka HERUDKOVÁ (203 Czech Republic, belonging to the institution), Nikola TOM (203 Czech Republic, belonging to the institution), Tereza HLUBINKOVÁ (203 Czech Republic, belonging to the institution), Veronika JANEČKOVÁ, Anna ĎURINÍKOVÁ (703 Slovakia, belonging to the institution), Jan VYDRA, Lukáš SEMERÁD (203 Czech Republic, belonging to the institution), Dana DVOŘÁKOVÁ (203 Czech Republic, belonging to the institution), Hana REMEŠOVÁ, Ela CEROVSKÁ, Petr CETKOVSKÝ, Pavel JINDRA, Tomáš SZOTKOWSKI, Pavel ŽÁK, Jiří MAYER (203 Czech Republic, belonging to the institution) and Zdeněk RÁČIL (203 Czech Republic, guarantor, belonging to the institution).
Edition British journal of haematology, England, Wiley-Blackwell, 2019, 0007-1048.
Other information
Original language English
Type of outcome Article in a journal
Field of Study 30205 Hematology
Country of publisher United States of America
Confidentiality degree is not subject to a state or trade secret
WWW URL
Impact factor Impact factor: 5.518
RIV identification code RIV/00216224:14110/19:00108507
Organization unit Faculty of Medicine
Doi http://dx.doi.org/10.1111/bjh.15916
UT WoS 000474639800013
Keywords in English acute myeloid leukaemia; next generation sequencing; persistent mutations; prognostic markers; survival
Tags 14110212, podil, rivok
Tags International impact, Reviewed
Changed by Changed by: Mgr. Pavla Foltynová, Ph.D., učo 106624. Changed: 31/3/2020 22:17.
Abstract
In this multi-centre study, we analysed the prognostic impact of mutations in 19 genes associated with myeloid malignancies in 258 newly diagnosed acute myeloid leukaemia patients (aged 19-70 years) undergoing intensive therapy. We identified five patient groups with different prognostic risks and different benefits from allogeneic hematopoietic stem cell transplantation (alloHSCT) within the intermediate cytogenetic risk group patients (n = 184). The most adverse prognosis was observed in patients with DNMT3A and FLT3-ITD co-mutation, whose survival could be significantly improved with alloHSCT. In contrast, the most favourable prognosis without any further benefit from alloHSCT was identified in patients with mutations in NPM1 or CEBPA, after exclusion of the unfavourable prognostic groups defined by mutations in DNMT3A, RUNX1 or genes from chromatin/spliceosome group. An additional analysis of 113 diagnosis-remission paired samples revealed that persistence of non-DNMT3A mutations (above 2% VAF) represented a further negative prognostic factor. The proposed model offers a possible molecular stratification and treatment guidance for intermediate cytogenetic risk group patients.
Links
NV15-25809A, research and development projectName: Národní program studia mutací a klonality leukemických buněk u pacientů s akutní myeloidní leukémií
PrintDisplayed: 21/7/2024 05:22